ADC Therapeutics SA (ADCT)
Makes antibody drugs that target cancer cells while sparing healthy tissue.
$1.12-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-58.4%
The outlook
ADCT trades at $1.12, well below both its 50- and 200-day moving averages and near the bottom of its 52-week range. Analyst consensus leans Buy, with an average price target around $5.00, roughly 346% above the current level. The stock's technical positioning remains weak despite bullish analyst sentiment.
What’s behind the score
Analyst consensusBuy — 1.8 avg of 3 analysts
Price trendBelow its 50- & 200-day averages
52-week range8% of the way from its 52-week low to high
Price targetAvg target +346% vs current price
Analyst price target
~12-month · 3 analysts$5.00average target+346.4% vs now
Now $1.12
Low $2.00High $10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$142.5M
52-wk high
$4.98
52-wk low
$0.78
50-day avg
$1.77
200-day avg
$3.41
Trailing P/E
—